(Q36993204)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982903%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

review article

1 reference

title

The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982903%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

0 references

N Miüller

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982903%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

M J Schwarz

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982903%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

1 reference

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982903%20AND%20SRC:MED&resulttype=core&format=json

Journal of neural transmission. Supplementum

9 January 2020

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982903%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982903%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

269-280

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982903%20AND%20SRC:MED&resulttype=core&format=json

Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Evidence for activation of microglia in patients with psychiatric illnesses

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Serologic evidence of prenatal influenza in the etiology of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Maternal infections and subsequent psychosis among offspring.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

The current status of the dopamine hypothesis of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

The neurochemical circuitry of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Cytokines production in chronic schizophrenia patients with or without paranoid behaviour.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

The genetics of schizophrenia: glutamate not dopamine?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Genetics of susceptibility to human infectious disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Cytokines in schizophrenia and the effects of antipsychotic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Clinical and laboratory evidence of autoimmunity in acute schizophrenia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Childhood meningitis, brain maturation and the risk of psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Tolerance, DCs and tryptophan: much ado about IDO

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Prostaglandins as modulators of immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Genetics of infectious disease resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Prenatal developmental disturbances in the limbic allocortex in schizophrenics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Grey matter changes can improve the prediction of schizophrenia in subjects at high risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Administration of interleukin-1 at birth affects dopaminergic neurons in adult mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Elevated plasma prostaglandin E2 levels in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Antibodies to the human 60 kDa heat-shock protein in patients with schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

The plasma levels of interleukin-12 in schizophrenia, major depression and bipolar mania: effects of psychotropic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Childhood central nervous system infections and risk for schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Significant frequency deviation of the class I polymorphism HLA-A10 in schizophrenic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Antibodies to infectious agents in individuals with recent onset schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

In vivo immunomodulatory effects of clozapine in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Analysis of a polymorphism in the promoter region of the tumor necrosis factor alpha gene in schizophrenia and bipolar disorder: further support for an association with schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

M-1/M-2 macrophages and the Th1/Th2 paradigm

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Immunological and infectious aspects of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Cellular immunity in schizophrenic patients before and during neuroleptic treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Psychotropic effects of COX-2 inhibitors--a possible new approach for the treatment of psychiatric disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Clinical effects of COX-2 inhibitors on cognition in schizophrenia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Is schizophrenia a neurodevelopmental disorder?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Glutamate receptor dysfunction and schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Influence of therapy on antibody-formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Decreased T cellular immune response in schizophrenic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Review of immunological and immunopathological findings in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

S100B in schizophrenic psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

[Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness]

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

A genome-wide autosomal screen for schizophrenia susceptibility loci in 71 families with affected siblings: support for loci on chromosome 10p and 6

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Increased cortical kynurenate content in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

T-helper-1 and T-helper-2 responses in psychiatric disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Prostaglandin-mediated control of rat brain kynurenic acid synthesis--opposite actions by COX-1 and COX-2 isoforms

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

On the production and disposition of quinolinic acid in rat brain and liver slices.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

(R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Tryptophan metabolism and oxidative stress in patients with Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Serum interleukin-18 levels are elevated in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Seasonality of births in schizophrenia and bipolar disorder: a review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Exposure to Prenatal and Childhood Infections and the Risk of Schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Is there a balance between microglia and astrocytes in regulating Th1/Th2-cell responses and neuropathologies?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_33

10.1007/978-3-211-73574-9_33

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982903%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference